The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Steven Brem
No Relationships to Disclose
 
Arati Suvas Desai
No Relationships to Disclose
 
Stephen Joseph Bagley
Consulting or Advisory Role - Bayer; Novocure; Sumitomo Dainippon Pharma Oncology
Research Funding - C2i genomics; GlaxoSmithKline; Guardant Health; Incyte; Lilly; Novocure; Tempus
Patents, Royalties, Other Intellectual Property - Co-inventor of intellectual property of the University of Pennsylvania licensed to Novartis: Combination Therapies of EGFRvIII Chimeric Antigen Receptors and PD-1 Inhibitors, US. Patent No. 62/809,245.
Travel, Accommodations, Expenses - Northwest Biotherapeutics
 
Sylvia Christine Kurz
Travel, Accommodations, Expenses - Optune
 
Macarena Ines De La Fuente
Consulting or Advisory Role - ADC Therapeutics (I); Agios; Pyramid Biosciences
Research Funding - ADC Therapeutics (I)
 
Seema Nagpal
Consulting or Advisory Role - Biocept; Novocure; Nurix; Pyramid Biosciences; Seagen
Research Funding - Agios (Inst); Berg Pharma (Inst); Inovio Pharmaceuticals (Inst); PharmAbcine (Inst)
 
Mary Roberta Welch
Research Funding - Boston Biomedical; Inovio Pharmaceuticals
Travel, Accommodations, Expenses - Boston Biomedical; Inovio Pharmaceuticals
 
Adilia Hormigo
No Relationships to Disclose
 
Peter A. J. Forsyth
Honoraria - Abbvie; BTG; Novocure
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; BTG; National Brain Tumor Society; Novocure; Tocagen; ZIOPHARM Oncology
Research Funding - Bankhead-Coley Cancer Research; Department of Defense; Florida Academic Cancer Center Alliance; NIH/NCI; Pfizer
Travel, Accommodations, Expenses - Abbvie; Bayer; Bristol-Myers Squibb; BTG; Inovio Pharmaceuticals; National Cancer Research Institute (NCRI); NCI; NIH; Physical Sciences Oncology Network
 
Jacob Joseph Mandel
No Relationships to Disclose
 
Simon Khagi
No Relationships to Disclose
 
Robert Aiken
No Relationships to Disclose
 
Tobias Walbert
Consulting or Advisory Role - AstraZeneca/MedImmune/Spirogen; Novocure; Orbus Therapeutics; Tocagen
Speakers' Bureau - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - NovoCure; Tocagen
 
Frank S. Lieberman
Research Funding - Imvax (Inst); Inovio Pharmaceuticals (Inst); Novocure (Inst)
 
Jana Portnow
Consulting or Advisory Role - In8Bio
Research Funding - Agios (Inst); Bayer Health (Inst); Denovo Biopharma (Inst); Novocure (Inst)
 
James Battiste
No Relationships to Disclose
 
Elisabeth Gillespie
Employment - Inovio Pharmaceuticals
Stock and Other Ownership Interests - Inovio Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent application submitted.
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Jeffrey Skolnik
Employment - Inovio Pharmaceuticals
Stock and Other Ownership Interests - Inovio Pharmaceuticals